Display options
Cite
Hwangbo W, Lee JH, Ahn S, et al. EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean J Pathol. 2013;47(2):107-15doi: 10.4132/KoreanJPathol.2013.47.2.107.
Hwangbo, W., Lee, J. H., Ahn, S., Kim, S., Park, K. H., Kim, C. H., & Kim, I. (2013). EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean journal of pathology, 47(2), 107-15. https://doi.org/10.4132/KoreanJPathol.2013.47.2.107
Hwangbo, Won, et al. "EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast." Korean journal of pathology vol. 47,2 (2013): 107-15. doi: https://doi.org/10.4132/KoreanJPathol.2013.47.2.107
Hwangbo W, Lee JH, Ahn S, Kim S, Park KH, Kim CH, Kim I. EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean J Pathol. 2013 Apr;47(2):107-15. doi: 10.4132/KoreanJPathol.2013.47.2.107. Epub 2013 Apr 24. PMID: 23667369; PMCID: PMC3647122.
Copy Download .nbib Format: NLM
Share it on

Korean J Pathol. 2013 Apr;47(2):107-15. doi: 10.4132/KoreanJPathol.2013.47.2.107. Epub 2013 Apr 24.

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast.

Korean journal of pathology

Won Hwangbo, Jeong Hyeon Lee, Sangjeong Ahn, Seojin Kim, Kyong Hwa Park, Chul Hwan Kim, Insun Kim

Affiliations

  1. Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

PMID: 23667369 PMCID: PMC3647122 DOI: 10.4132/KoreanJPathol.2013.47.2.107

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment.

METHODS: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification.

RESULTS: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2(+), EGFR(+), cytokeratin 5/6(-) (CK5/6(-)) group, 11.2% of the HER-2(-), EGFR(+), CK5/6(-) group, and 19.1% of the HER-2(-), EGFR(+), CK5/6(+) group. FISH-positive cases were detected in 8.3% of the EGFR protein 1(+) expression cases, 15.9% of 2(+) expression cases, and 38.5% of 3(+) expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6.

CONCLUSIONS: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.

Keywords: Breast neoplasms; Gene amplification; Protein expression; Receptor, epidermal growth factor

References

  1. J Clin Oncol. 2004 Mar 1;22(5):854-63 - PubMed
  2. BMC Cancer. 2009 Jun 18;9:192 - PubMed
  3. J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):485-98 - PubMed
  4. J Clin Pathol. 2009 Nov;62(11):970-7 - PubMed
  5. Cancer Res. 2004 Dec 1;64(23):8534-40 - PubMed
  6. Cancer Genet Cytogenet. 2010 Dec;203(2):222-9 - PubMed
  7. Ann Oncol. 2007 Apr;18(4):752-60 - PubMed
  8. Breast Cancer. 2014 Jan;21(1):66-74 - PubMed
  9. Pathol Int. 2008 Jan;58(1):17-25 - PubMed
  10. J Clin Oncol. 2007 Jan 1;25(1):118-45 - PubMed
  11. Clin Cancer Res. 2002 Nov;8(11):3454-60 - PubMed
  12. Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25 - PubMed
  13. Clin Med Res. 2009 Jun;7(1-2):4-13 - PubMed
  14. Histopathology. 2011 Aug;59(2):264-73 - PubMed
  15. Mod Pathol. 2005 Aug;18(8):1027-33 - PubMed
  16. Breast Cancer Res Treat. 2012 Nov;136(2):331-45 - PubMed
  17. Mod Pathol. 2006 Feb;19(2):264-71 - PubMed
  18. Clin Cancer Res. 2009 Nov 1;15(21):6639-48 - PubMed
  19. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1500-4 - PubMed
  20. Clin Cancer Res. 2007 Apr 15;13(8):2329-34 - PubMed
  21. J Transl Med. 2012 Sep 19;10 Suppl 1:S4 - PubMed
  22. Histopathology. 2006 Jul;49(1):22-34 - PubMed
  23. Cancer Biol Ther. 2008 Nov;7(11):1818-28 - PubMed
  24. Expert Rev Mol Diagn. 2008 Jul;8(4):417-34 - PubMed
  25. Lancet Oncol. 2005 May;6(5):279-86 - PubMed
  26. N Engl J Med. 2005 Oct 20;353(16):1659-72 - PubMed
  27. Biologics. 2012;6:337-45 - PubMed
  28. Eur J Surg Oncol. 2007 Oct;33(8):956-60 - PubMed

Publication Types